Scholarlink

Background <p>Based on the results of the JCOG1212 trial, superselective intra-arterial infusion chemoradiotherapy (IA-CRT) has become a standard treatment option for patients with locally advanced maxillary sinus carcinoma (LA-MSC), especially those with T4a disease, in Japan. This study aimed to evaluate the real-world effectiveness of IA-CRT compared with systemic intravenous chemoradiotherapy (IV-CRT) in patients with LA-MSC.</p> Methods <p>We retrospectively analyzed data from patients with T3 and T4 N0M0 maxillary sinus carcinoma who were treated with IA-CRT or IV-CRT between 2011 and 2017, using data from the Head and Neck Cancer Registry of Japan. The primary endpoint was the 5-year local control rate (LCR), and the secondary endpoints were overall survival (OS) and progression-free survival (PFS). Survival analyses were performed using inverse probability of treatment weighting (IPTW) adjustment.</p> Results <p>Among 1,329 registered patients, 507 received definitive chemoradiotherapy as initial treatment, including 373 patients treated with IA-CRT (median follow-up, 46 months) and 134 treated with IV-CRT (median follow-up, 31 months). After IPTW adjustment, the 5-year LCR was significantly higher in the IA-CRT group than in the IV-CRT group (67.0% vs. 46.0%; hazard ratio, 0.61; 95% confidence interval, 0.44–0.84; <i>p</i> = 0.0023). OS and PFS showed no significant differences between the two groups.</p> Conclusions <p>IA-CRT was associated with improved local control compared with IV-CRT in patients with LA-MSC. Although its impact on survival outcomes remains uncertain, these findings provide real-world evidence that complements the results of the JCOG1212 trial and inform treatment selection in routine clinical practice.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Clinical effectiveness of intra-arterial chemoradiotherapy for advanced maxillary sinus carcinoma: based on the reports of the head and neck cancer registry of Japan

  • 期刊论文

  • 发表日期：

    2026年5月26日

查看全文
  • Masahiro Hemmi,
  • Daisuke Sano,
  • Daisuke Kawakita,
  • Seiichi Yoshimoto,
  • Megumi Kitayama,
  • Ken-Ichi Nibu,
  • Nobuhiko Oridate

摘要

Background

Based on the results of the JCOG1212 trial, superselective intra-arterial infusion chemoradiotherapy (IA-CRT) has become a standard treatment option for patients with locally advanced maxillary sinus carcinoma (LA-MSC), especially those with T4a disease, in Japan. This study aimed to evaluate the real-world effectiveness of IA-CRT compared with systemic intravenous chemoradiotherapy (IV-CRT) in patients with LA-MSC.

Methods

We retrospectively analyzed data from patients with T3 and T4 N0M0 maxillary sinus carcinoma who were treated with IA-CRT or IV-CRT between 2011 and 2017, using data from the Head and Neck Cancer Registry of Japan. The primary endpoint was the 5-year local control rate (LCR), and the secondary endpoints were overall survival (OS) and progression-free survival (PFS). Survival analyses were performed using inverse probability of treatment weighting (IPTW) adjustment.

Results

Among 1,329 registered patients, 507 received definitive chemoradiotherapy as initial treatment, including 373 patients treated with IA-CRT (median follow-up, 46 months) and 134 treated with IV-CRT (median follow-up, 31 months). After IPTW adjustment, the 5-year LCR was significantly higher in the IA-CRT group than in the IV-CRT group (67.0% vs. 46.0%; hazard ratio, 0.61; 95% confidence interval, 0.44–0.84; p = 0.0023). OS and PFS showed no significant differences between the two groups.

Conclusions

IA-CRT was associated with improved local control compared with IV-CRT in patients with LA-MSC. Although its impact on survival outcomes remains uncertain, these findings provide real-world evidence that complements the results of the JCOG1212 trial and inform treatment selection in routine clinical practice.